NASDAQ:CERSCerus Stock Price, Forecast & News

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CERS stock has increased by 43.8% and is now trading at $6.8450. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cerus.

Cerus is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Cerus.

Cerus Co. (NASDAQ:CERS) posted its earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.00. The biotechnology company earned $18.61 million during the quarter, compared to analysts' expectations of $17.60 million. Cerus had a negative net margin of 90.97% and a negative return on equity of 93.16%. View Cerus' earnings history.

Cerus updated its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $111.9 million.

4 brokerages have issued 1-year target prices for Cerus' shares. Their forecasts range from $6.50 to $9.00. On average, they expect Cerus' share price to reach $7.63 in the next year. This suggests a possible upside of 11.4% from the stock's current price. View analysts' price targets for Cerus.

Press coverage about CERS stock has trended very negative on Thursday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cerus earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Cerus.

Some companies that are related to Cerus include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Meridian Bioscience (VIVO), OraSure Technologies (OSUR), Anika Therapeutics (ANIK) and Antares Pharma (ATRS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), Opko Health (OPK), Grayscale Bitcoin Trust (Btc) (GBTC), ACADIA Pharmaceuticals (ACAD), Aduro BioTech (ADRO) and Celldex Therapeutics (CLDX).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $6.85.

Cerus has a market capitalization of $1.12 billion and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.

The official website for Cerus is www.cerus.com.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]